Real-World Comparative Survival Outcomes of First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Cohort Study.
- 1School of Medicine, Tianjin University, Tianjin, China.
- 2Department of Thoracic Surgery, Tianjin University Haihe Hospital, Tianjin 300350, China.
- 3Department of Thoracic Surgery, Tianjin Chest Hospital (Affiliated Hospital of Tianjin University), Tianjin 300222, China.
Abstract
Background
Extensive-stage small-cell lung cancer (ES-SCLC) remains an aggressive malignancy with poor survival despite platinum-etoposide chemotherapy. Although serplulimab plus chemotherapy has demonstrated a survival benefit in randomized trials, comparative real-world evidence remains limited. We therefore evaluated survival outcomes with first-line serplulimab plus chemotherapy versus chemotherapy alone in patients with ES-SCLC.Methods
We conducted a single-center retrospective cohort study at Tianjin Chest Hospital. Patients with ES-SCLC who initiated first-line platinum-etoposide-based chemotherapy between January 2020 and December 2024 were screened, with follow-up censored on May 1, 2025. Patients were classified according to whether serplulimab was incorporated into first-line treatment. The primary endpoint was overall survival (OS), and the secondary endpoint was real-world progression-free survival (rwPFS). Treatment effects were estimated using Kaplan-Meier analyses and Cox proportional hazards models. Because of the limited sample size and event count, the primary adjusted Cox model was restricted to prespecified clinical covariates. Sensitivity analyses included treatment-year adjustment, restriction to patients treated during 2022-2024, reduced propensity score overlap weighting and stabilized trimmed inverse probability of treatment weighting (IPTW).Results
The final cohort included 112 patients, of whom 30 received serplulimab plus chemotherapy and 82 received chemotherapy alone. Median OS was 18.69 months with serplulimab plus chemotherapy and 11.86 months with chemotherapy alone (HR = 0.49, 95% CI: 0.27-0.90; P = 0.021; log-rank P = 0.017). The association remained significant after parsimonious clinical adjustment (adjusted HR = 0.50, 95% CI: 0.27-0.93; P = 0.028). Sensitivity analyses yielded directionally similar OS estimates across treatment-year adjustment, 2022-2024 restriction, overlap weighting, and stabilized trimmed IPTW. Median rwPFS was also numerically longer with serplulimab plus chemotherapy, although the difference was not statistically significant (10.64 vs 8.18 months; HR = 0.76, 95% CI: 0.48-1.20; P = 0.244).Conclusions
In this single-center real-world cohort, first-line serplulimab plus chemotherapy was associated with longer OS than chemotherapy alone in patients with ES-SCLC, whereas the rwPFS difference was not statistically significant. The findings were directionally supported by multiple sensitivity analyses but should be interpreted cautiously because of the limited sample size, potential calendar-time confounding, and incomplete standardized safety assessment. Larger prospective studies are needed for confirmation.
Related
- Case Report: Serplulimab-induced checkpoint inhibitor pneumonitis in extensive-stage small cell lung cancer with underlying COPD: a case report and literature review.
- Peripheral Lymphocyte Subsets Predict Efficacy and Overall Survival in Gastric Cancer Patients Receiving Preoperative Chemotherapy: A Retrospective Cohort Study
- Pretreatment Body Composition and Its Association with Pathologic Complete Response and Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Retrospective Cohort Study
- Neurological syndrome with CSF anti-Hu positivity during serplulimab therapy in extensive-stage small-cell lung cancer: a case report
- Bedside Bioimpedance and Simple Functional Tests Identify Muscle Function Impairment Predicting Overall Survival in Chemotherapy-treated Metastatic Urothelial Carcinoma: A Retrospective Pilot Study
BibTeX
@article{jing2026realworld,
title = {{Real-World Comparative Survival Outcomes of First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Cohort Study.}},
author = {Yuhao Jing and Miao Li and Songxiang Li and Yifan Zhao and Zhenbao Zhou and Xin Li and Meng Wang},
journal = {Journal of Cancer},
year = {2026},
month = oct,
doi = {10.7150/jca.140183},
url = {https://europepmc.org/article/MED/42910403},
note = {CC BY},
}
RIS
TY - JOUR
TI - Real-World Comparative Survival Outcomes of First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Cohort Study.
AU - Yuhao Jing
AU - Miao Li
AU - Songxiang Li
AU - Yifan Zhao
AU - Zhenbao Zhou
AU - Xin Li
AU - Meng Wang
PY - 2026
DA - 2026/10/16
JO - Journal of Cancer
DO - 10.7150/jca.140183
UR - https://europepmc.org/article/MED/42910403
AB - Background Extensive-stage small-cell lung cancer (ES-SCLC) remains an aggressive malignancy with poor survival despite platinum-etoposide chemotherapy. Although serplulimab plus chemotherapy has demonstrated a survival benefit in randomized trials, comparative real-world evidence remains limited. We therefore evaluated survival outcomes with first-line serplulimab plus chemotherapy versus chemotherapy alone in patients with ES-SCLC.Methods We conducted a single-center retrospective cohort study at Tianjin Chest Hospital. Patients with ES-SCLC who initiated first-line platinum-etoposide-based chemotherapy between January 2020 and December 2024 were screened, with follow-up censored on May 1, 2025. Patients were classified according to whether serplulimab was incorporated into first-line treatment. The primary endpoint was overall survival (OS), and the secondary endpoint was real-world progression-free survival (rwPFS). Treatment effects were estimated using Kaplan-Meier analyses and Cox proportional hazards models. Because of the limited sample size and event count, the primary adjusted Cox model was restricted to prespecified clinical covariates. Sensitivity analyses included treatment-year adjustment, restriction to patients treated during 2022-2024, reduced propensity score overlap weighting and stabilized trimmed inverse probability of treatment weighting (IPTW).Results The final cohort included 112 patients, of whom 30 received serplulimab plus chemotherapy and 82 received chemotherapy alone. Median OS was 18.69 months with serplulimab plus chemotherapy and 11.86 months with chemotherapy alone (HR = 0.49, 95% CI: 0.27-0.90; P = 0.021; log-rank P = 0.017). The association remained significant after parsimonious clinical adjustment (adjusted HR = 0.50, 95% CI: 0.27-0.93; P = 0.028). Sensitivity analyses yielded directionally similar OS estimates across treatment-year adjustment, 2022-2024 restriction, overlap weighting, and stabilized trimmed IPTW. Median rwPFS was also numerically longer with serplulimab plus chemotherapy, although the difference was not statistically significant (10.64 vs 8.18 months; HR = 0.76, 95% CI: 0.48-1.20; P = 0.244).Conclusions In this single-center real-world cohort, first-line serplulimab plus chemotherapy was associated with longer OS than chemotherapy alone in patients with ES-SCLC, whereas the rwPFS difference was not statistically significant. The findings were directionally supported by multiple sensitivity analyses but should be interpreted cautiously because of the limited sample size, potential calendar-time confounding, and incomplete standardized safety assessment. Larger prospective studies are needed for confirmation.
SN - 1837-9664
ER -